Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib
Merck discontinues the clinical development of nemtabrutinib and all three Phase 3 BELLWAVE trials following a benefit-risk assessment that raised concerns about the investigational BTK inhibitor.
Merck | 20/11/2026 | By News Bureau
Merck Initiates Phase 3 ENHANCE-3 Trial of Ohtuvayre for COPD Exacerbation Prevention
Merck initiates the phase 3 ENHANCE-3 clinical trial to evaluate Ohtuvayre for preventing COPD exacerbations in adults receiving standard-of-care treatment.
Merck | 05/11/2026 | By News Bureau
Merck to Acquire Silence Therapeutics for Rare Disease siRNA
Merck has entered into a definitive agreement to acquire biotech company Silence Therapeutics, focused on siRNA-therapies in areas of high unmet need.
Merck | 21/10/2026 | By News Bureau | 117
Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa
Merck reported Phase 2b results for investigational tulisokibart in patients with moderate to severe hidradenitis suppurativa.
Merck | 01/10/2026 | By News Bureau | 155
FDA Updates Winrevair Label With Phase 3 HYPERION Data
Merck’s Winrevair label has been updated by the US FDA to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension.
Merck | 23/09/2026 | By News Bureau | 206
Japan Approves Merck's Keytruda Qlex for Subcutaneous Use
Merck’s Keytruda Qlex receives MHLW approval in Japan for subcutaneous use across all locally approved Keytruda indications.
Merck | 22/09/2026 | By News Bureau | 131
Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC
Merck’s Keytruda plus Padcev receives a positive CHMP opinion for perioperative treatment of adults with resectable muscle-invasive bladder cancer, with the EC set to review the recommendation.
Merck | 19/09/2026 | By News Bureau | 136
Merck Expands Jigani Facility to Boost Life Science Manufacturing
Merck has invested approximately Euro 13 million to expand its Jigani, Bengaluru facility with new biological buffer manufacturing capabilities.
Merck | 18/09/2026 | By News Bureau | 265
Merck Delivers Robust Q2 2026 Performance
Merck reported strong Q2 2026 results with 4.1 percent organic sales growth, higher EBITDA, upgraded full-year guidance and planned Bio-Techne acquisition.
Merck | 06/08/2026 | By News Bureau | 183
Merck Wins US FDA Breakthrough Therapy Designation Status for Enpatoran in Lupus
Merck has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for enpatoran in lupus patients with active skin manifestations, advancing a potential first approved treatment for cutaneous lupus.
Merck | 09/07/2026 | By News Bureau | 130
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy